Phase 1Completed
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer (TACTIVE-E)
A Phase 1b Trial of ARV-471 in Combination With Everolimus in Patients With ER+, HER2- Advanced or Metastatic Breast Cancer
- Sponsor
- Arvinas Estrogen Receptor, Inc. (Industry)
- Enrolment
- 32 enrolled
- Conditions
- Breast Cancer
- Interventions
- ARV-471 in combination with Everolimus
- Ages
- adults, older adults
- Registry
- NCT05501769
Full record on ClinicalTrials.gov
From the registry
A phase 1b study to assess the combination of ARV-471 and everolimus in participants with advanced or metastatic ER+/HER2- breast cancer.
Primary outcomes
- Incidence of dose limiting toxicities of ARV-471 in combination with everolimus
- Recommended Phase 2 Dose (RP2D) for ARV-471 in combination with everolimus
- Number of participants with adverse events as a measure of safety and tolerability of ARV-471 in combination with everolimus
- Incidence of laboratory abnormalities as a measure of safety and tolerability of ARV-471 in combination with everolimus
History
Last registry update
Study completion
Primary completion
Started
Registered